Recent developments include the company’s rebranding to Avai Bio and launch of a new website, the launch of Klothonova with Austrianova to develop age-related cellular therapies, and the mutual termination of the joint venture and license agreement with Ainnova Tech.

• Avai Bio completed rebranding from Avant Technologies and launched a new website in February 2026 [N7].
• The company and Austrianova launched Klothonova in October 2025 to develop age-related cellular therapies using the longevity protein Klotho [N8].
• Avai Bio and Ainnova Tech mutually terminated their joint venture and license agreement in May 2026, dissolving the related joint venture entity [S18][S19].
• Recent market news includes commodity price movements and macroeconomic factors affecting broader markets [N1][N2][N3][N4][N5][N6].

Avai Bio’s advanced AI platform with unique unsupervised and supervised learning capabilities could enable innovative solutions that transform businesses and society. Strategic acquisitions and partnerships provide resources and expertise to develop and commercialize AI technologies. The company’s rebranding and focus on biotech-related AI applications, such as age-related cellular therapies, may open new market opportunities. Successful execution of its business plan and capital raising could support growth and technology development.

The company has a limited operating history, has not generated revenue, and has incurred significant net losses and negative cash flows. It depends heavily on raising additional capital, which may dilute existing shareholders and may not be available on favorable terms. The termination of its joint venture with Ainnova Tech indicates challenges in partnerships. Commercialization of proprietary AI and digital assets remains speculative. The company’s stock trades on the OTC QB with limited liquidity and high volatility, increasing investment risk.

Avai Bio’s moat is based on its proprietary AI technology that combines unsupervised clustering with supervised learning to enable true learning from experience and reasoning. The company’s acquisitions provide it with full-stack software development and cloud services capabilities. However, the company operates in a highly competitive and rapidly evolving AI and technology consulting industry, with limited operating history and unproven commercialization of its assets, which constrains its moat strength.

• Limited Operating History and Evolving Industry: The company’s limited operating history in a rapidly evolving AI and technology industry makes it difficult to evaluate future prospects and increases execution risk.
• Lack of Revenue and Profitability: The company has not generated revenue in recent fiscal years and has incurred significant net losses, with no assurance of achieving profitability.
• Dependence on Capital Raising: The company depends on raising equity or debt capital to fund operations and growth, which may be dilutive, costly, or unavailable on acceptable terms.
• Commercialization Risk: Commercializing acquired AI and digital assets remains speculative, and failure to do so could harm business prospects.
• Stock Market Risks: The company’s common stock trades on the OTC QB marketplace with limited liquidity and potential for significant price volatility, which may affect shareholder value.

• Avai Bio, Inc. (formerly Avant Technologies Inc.) is a technology company specializing in acquiring, creating, and developing innovative technologies utilizing artificial intelligence (AI) and providing IT consulting services [S1].
• The company considers itself a native expert in AI-based information technology [S1].
• Key acquisitions include Avant! AI and a Joint Venture and License Agreement with Ainnova Tech Inc., providing resources in full-stack software development, database management, data integration, project management, and cloud services [S1].
• The company’s AI technology uses unsupervised clustering and proprietary supervised learning techniques to improve data efficiency and enable true learning from experience and reasoning [S1].
• On February 3, 2026, the company changed its corporate name from Avant Technologies, Inc. to Avai Bio, Inc., retaining the ticker symbol AVAI [S1].
• The company acquired assets including Avant! AI, InstantFAME, and previously acquired and later divested Wired4Health assets [S1, S16, S17].
• The company has a limited operating history and operates in an evolving industry, which makes evaluation of future prospects difficult [S1, S2].
• The company has not generated revenue during fiscal years ended March 31, 2026 and 2025 [S7].
• The company incurred net losses of $1,749,509 for the year ended March 31, 2026 and $1,142,115 for the year ended March 31, 2025 [S7].
• Operating expenses for fiscal year 2026 were $1,480,191, including consulting, general and administrative, marketing, professional fees, and research and development expenses [S7].
• The company’s net cash used in operating activities was $1,009,844 for fiscal year 2026 [S8].
• Net cash from financing activities was $951,936 for fiscal year 2026, primarily from capital stock issued, convertible notes payable, and loans [S8].
• As of March 31, 2026, the company had cash and equivalents of $23,145, current assets of $89,340, current liabilities of $3,387,851, resulting in a current ratio of 0.03 and cash ratio of 0.01 [S7, S8].
• The company had a stockholders’ deficit of $2,815,155 and an accumulated deficit of $5,868,019 as of March 31, 2026 [S7].
• The company’s business plan is speculative and unproven, with no assurance of achieving profitability or curtailing losses [S1, S2].
• The company depends on raising additional capital through equity or debt financings to support operations and growth, with plans to raise about $10 million to fully implement its business plan [S1, S2].
• The company’s common stock is quoted on the OTC QB marketplace under the ticker AVAI, with limited liquidity and potential for significant price volatility [S1, S2].
• The company faces risks including limited operating history, inability to generate positive cash flow, dependence on capital raising, potential dilution, and challenges in commercializing acquired technologies [S1, S2, S15, S22].
• The company’s joint venture and license agreement with Ainnova Tech Inc. was mutually terminated in May 2026, dissolving the related joint venture entity [S18, S19].
• Recent news includes the company’s rebranding to Avai Bio and launch of a new website in February 2026 [N7].
• The company and Austrianova launched Klothonova in October 2025 to develop age-related cellular therapies using the longevity protein Klotho [N8].
• The company has engaged in strategic biotech partnerships for innovative cell-based therapies [N8].
• Recent market news unrelated to the company includes commodity price movements and macroeconomic factors [N1, N2, N3, N4, N5, N6].